Dendritic cells generated with PDL-1 checkpoint blockade for treatment of advanced pancreatic cancer.

Nesselhut, Jan; Marx, D; Cillien, N.; Lange, Hans; Regalo, Gonçalo; Herrmann, Michael; Hupfeld, Timo; Chang, Raymond; Neßelhut, Thomas

doi:10.1200/jco.2015.33.15_suppl.4128

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ICIs have also been added to dendritic cell vaccines to enhance their efficacy, given the expression of PDL-1 on dendritic cells. There has been a stabilization of disease under this association in five of 10 patients that had previously failed the dendritic vaccine alone [9].…”

Section: Review Immunotherapymentioning

confidence: 95%

Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?

Delma¹

2020

Cureus

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma is characterized by its high morbidity, and curative drugs are still lacking. In addition to immunotherapy, other molecular targeted therapeutics, such as stroma depleting agents, have been evaluated, given the abundant desmoplastic stroma that is considered a protective shield for tumor cells. However, the unexpected poor outcome has raised the debate on whether desmoplasia promotes or restrains tumor cell spread. After reviewing these key points in this paper, an approach taking advantage of desmoplasia and immune cells to besiege the tumoral sites will be proposed. Based on the available literature, the feasibility and potential limitations of this strategy will be discussed.

show abstract

Section: Review Immunotherapymentioning

confidence: 95%

Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?

Delma¹

2020

Cureus

View full text Add to dashboard Cite

show abstract

“…A German group isolated antigen-primed monocyte derived dendritic cells (DCs) from 44 patients with stage IV pancreatic cancer who failed first-line chemotherapy and demonstrated a median OS of 8 months with DC vaccine alone; however combination DC vaccine and PD-L1 blockade was able to induce secondary stabilization of disease of 4-8 months in 5/10 patients who failed to respond to previous DC therapy [46]. Preliminary results including 2 partial responses (PRs) were observed from a pilot study by the same group investigating lower dose nivolumab in combination with DC vaccine therapy in 7 patients with stage IV pancreatic cancer ( Table 2) [47].…”

Section: Vaccinesmentioning

confidence: 99%

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single‐agent checkpoint blockade

Gong

Hendifar

Tuli

et al. 2018

Clinical & Translational Med

View full text Add to dashboard Cite

Immune checkpoint inhibitors have demonstrated broad single-agent antitumor activity and a favorable safety profile that render them attractive agents to combine with other systemic anticancer therapies. Pancreatic cancer has been fairly resistant to monotherapy blockade of programmed cell death protein 1 receptor, programmed death ligand 1, and cytotoxic T-lymphocyte associated protein 4. However, there is a growing body of preclinical evidence to support the rational combination of checkpoint inhibitors and various systemic therapies in pancreatic cancer. Furthermore, early clinical evidence has begun to support the feasibility and efficacy of checkpoint inhibitor-based combination therapy in advanced pancreatic cancer. Despite accumulating preclinical and clinical data, there remains several questions as to the optimal dosing and timing of administration of respective agents, toxicity of combination strategies, and mechanisms by which immune resistance to single-agent checkpoint blockade are overcome. Further development of biomarkers is also important in the advancement of combination systemic therapies incorporating checkpoint blockade in pancreatic cancer. Results from an impressive number of ongoing prospective clinical trials are eagerly anticipated and will seek to validate the viability of combination immuno-oncology strategies in pancreatic cancer.

show abstract

“…In addition, anticancer vaccination can also be studied in combination with immune checkpoint blockade. Preliminary results of a trial with monocyte-derived DCs combined with PD-L1 checkpoint blockade for patients with pretreated advanced pancreatic cancer were presented in 2016 ASCO gastrointestinal symposium: median OS was reported to reach 18 months after primary diagnosis 54 .…”

Section: Future Perspectivementioning

confidence: 99%

Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers

Kim

2016

J. Cancer

View full text Add to dashboard Cite

Cancer immunotherapy is at dawn of the Renaissance after the Medieval Dark Ages. Recent advances of understanding tumor immunology and molecular drug development are leading us to the epoch of cancer immunotherapy. Some types of immunotherapy have shown to provide survival benefit for patients with solid tumors such as malignant melanoma, renal cell carcinoma, or non-small cell lung cancer. Several studies have suggested that immune checkpoint inhibition might be effective in some patients with gastrointestinal cancers. However, the era of cancer immunotherapy in gastrointestinal cancers is still in an inchoate stage. Here we briefly review the current status and perspective of immunotherapeutic approaches in patients with gastrointestinal cancers.

show abstract

Dendritic cells generated with PDL-1 checkpoint blockade for treatment of advanced pancreatic cancer.

Cited by 6 publications

References 0 publications

Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?

Besieging the Tumoral Sites: Could It Be an Alternative Therapeutic Strategy in Ductal Pancreatic Adenocarcinoma?

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single‐agent checkpoint blockade

Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers

Contact Info

Product

Resources

About